Vaccine-Preventable Diseases in the Age of COVID-19: How Can We Keep Them at Bay?
Keeping up with pediatric and adult immunization schedules in the COVID-19 era has become significantly more challenging. Existing problems of vaccine hesitancy and missed opportunities are being exacerbated by physical restrictions, and clinicians are struggling to prioritize services and treatment. Clinicians need to be aware of pertinent updates to immunization recommendations across the age spectrum in order to keep vaccine-preventable diseases and complications in check. This webcast will offer expert perspectives and guidance on how to maintain routine immunization schedules in children, adolescents, and adults during the COVID-19 pandemic and beyond.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), infectious disease specialists, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
After completing this activity, the participant should be better able to:
• Identify innovative ways to keep educating patients and family members about the benefits of immunizations across the age spectrum
• Recognize and address common and new misconceptions about immunizations and vaccine-preventable diseases in the era of COVID-19
• Employ practical steps and strategies to maintain immunization schedules amidst COVID-19 challenges
Gregory A. Poland, MD (Chair)
Mary Lowell Leary Emeritus Professor of Medicine
Distinguished Investigator, Mayo Clinic
Director, Mayo Vaccine Research Group
Dr. Poland discloses the following:
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Sanofi Pasteur, GlaxoSmithKline, Emergent Biosolutions, Medicago, and Dynavax. Dr. Poland holds two patents related to vaccinia and measles peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Stefan Gravenstein, MD, MPH
David S. Greer Professor of Geriatrics
Director, Division of Geriatrics and Palliative Care
Alpert Medical School and School of Public Health
Dr. Gravenstein discloses the following:
Consulting Fees: Janssen, Seqirus, Sanofi
Contracted Research: Seqirus, Sanofi, Pfizer
Victoria A. Statler, MD, MSc
Associate Professor of Pediatrics
Director, Pediatric Transplant Infectious Diseases Clinical Service
Norton Children’s Hospital
Affiliated with the University of Louisville
Dr. Statler discloses the following:
Consulting Fees: MeMed
Contracted Research: Sanofi, Astellas, Gilead
EDUCATIONAL GRANT SUPPORT
This educational activity is supported by educational grants from GlaxoSmithKline and Merck Sharp & Dohme Corp.
Jointly provided by Postgraduate Institute for Medicine and Tarsus Medical Education.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and TME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 1.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-20-2474-H06-P
Type of Activity: Knowledge
ACCREDITED PROVIDER DISCLOSURE
The PIM planners and managers have nothing to disclose. The TME planners and managers have nothing to disclose.
CONFLICT OF INTEREST DISCLOSURE POLICY
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 1, 2020 through December 1, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation. Upon completing, your certificate will be made available immediately.
For questions about the accreditation of this activity, please visit http://www.pimed.com/
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.